CN102711474B - 喹唑啉化合物 - Google Patents

喹唑啉化合物 Download PDF

Info

Publication number
CN102711474B
CN102711474B CN201080060451.4A CN201080060451A CN102711474B CN 102711474 B CN102711474 B CN 102711474B CN 201080060451 A CN201080060451 A CN 201080060451A CN 102711474 B CN102711474 B CN 102711474B
Authority
CN
China
Prior art keywords
amino
methoxy
methyl
quinazolinyl
benzenesulfonamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080060451.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN102711474A (zh
Inventor
L.S.卡兰德
B.G.洛霍恩
J.菲尔普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC
Publication of CN102711474A publication Critical patent/CN102711474A/zh
Application granted granted Critical
Publication of CN102711474B publication Critical patent/CN102711474B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/056Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201080060451.4A 2009-11-03 2010-11-01 喹唑啉化合物 Expired - Fee Related CN102711474B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25764609P 2009-11-03 2009-11-03
US61/257,646 2009-11-03
PCT/US2010/054927 WO2011056740A1 (en) 2009-11-03 2010-11-01 Quinazoline compounds

Publications (2)

Publication Number Publication Date
CN102711474A CN102711474A (zh) 2012-10-03
CN102711474B true CN102711474B (zh) 2014-09-10

Family

ID=43970282

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080060451.4A Expired - Fee Related CN102711474B (zh) 2009-11-03 2010-11-01 喹唑啉化合物

Country Status (13)

Country Link
US (1) US8859571B2 (https=)
EP (1) EP2501233B1 (https=)
JP (1) JP5836963B2 (https=)
KR (1) KR101736521B1 (https=)
CN (1) CN102711474B (https=)
AU (1) AU2010315361B2 (https=)
BR (1) BR112012010524A2 (https=)
CA (1) CA2779989A1 (https=)
EA (1) EA021439B1 (https=)
ES (1) ES2523465T3 (https=)
IL (1) IL219504A (https=)
MX (1) MX2012005155A (https=)
WO (1) WO2011056740A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5603883B2 (ja) * 2009-02-17 2014-10-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング B−Rafキナーゼを阻害するためのピリミドピリミジン誘導体
CN103159685A (zh) * 2013-04-11 2013-06-19 苏州立新制药有限公司 4-氯-6,7-二(2-甲氧基乙氧基)喹唑啉的制备方法
JP6527513B2 (ja) * 2013-11-20 2019-06-05 シグナルケム・ライフサイエンシーズ・コーポレイションSignalchem Lifesciences Corporation Tamファミリーキナーゼ阻害剤としてのキナゾリン誘導体
CN105849044B (zh) 2013-12-26 2018-10-26 埃克森美孚研究工程公司 Zsm-48晶体的合成
CN111868039A (zh) * 2017-09-26 2020-10-30 加利福尼亚大学董事会 用于治疗癌症的组合物和方法
JP7785663B2 (ja) 2019-09-16 2025-12-15 ノバルティス アーゲー 二機能性分解誘導薬及びそれらの使用方法
WO2023049312A1 (en) 2021-09-23 2023-03-30 Erasca, Inc. Egfr inhibitor polymorph forms

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
PT2213661E (pt) 2003-09-26 2011-12-15 Exelixis Inc Moduladores de c-met e métodos de uso
CN103626742B (zh) * 2005-11-01 2017-04-26 塔格根公司 激酶的联-芳基间-嘧啶抑制剂

Also Published As

Publication number Publication date
ES2523465T3 (es) 2014-11-26
US8859571B2 (en) 2014-10-14
JP2013510155A (ja) 2013-03-21
JP5836963B2 (ja) 2015-12-24
CA2779989A1 (en) 2011-05-12
US20120220588A1 (en) 2012-08-30
EP2501233A1 (en) 2012-09-26
EA201290243A1 (ru) 2012-12-28
KR101736521B1 (ko) 2017-05-16
CN102711474A (zh) 2012-10-03
IL219504A (en) 2016-09-29
BR112012010524A2 (pt) 2017-12-12
KR20120112441A (ko) 2012-10-11
EP2501233B1 (en) 2014-09-24
WO2011056740A1 (en) 2011-05-12
MX2012005155A (es) 2012-08-31
AU2010315361A1 (en) 2012-05-24
AU2010315361B2 (en) 2014-06-12
EA021439B1 (ru) 2015-06-30
IL219504A0 (en) 2012-06-28
EP2501233A4 (en) 2013-06-19

Similar Documents

Publication Publication Date Title
CN114040911B (zh) 作为nav1.8抑制剂的2,3-二氢喹唑啉化合物
ES3036467T3 (en) Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
AU2015222584B2 (en) 2,4-disubstituted phenylene-1,5-diamine derivatives and applications thereof, and pharmaceutical compositions and pharmaceutically acceptable compositions prepared therefrom
US9890168B2 (en) 2,4-disubstituted 7H-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof
CN102711474B (zh) 喹唑啉化合物
EP2523559A1 (en) Compounds and methods
CN112313207B (zh) 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用
WO2015060373A1 (ja) キナゾリノンおよびイソキノリノン誘導体
KR20170054421A (ko) 브로모도메인 억제제로서의 테트라하이드로퀴놀린 유도체
US20120157482A1 (en) Compounds and methods
WO2011088031A1 (en) Compounds and methods
CN113943251B (zh) 双环庚烯基氨基取代的氮杂芳环类化合物及其医药用途
HK40090980A (zh) 杂芳基衍生物、其制备方法、及含其作为有效成分的药物组合物
HK40074494A (en) Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
TW202246261A (zh) 作為抗癌劑的化合物
HK40074494B (zh) 杂芳基衍生物、其制备方法、及含其作为有效成分的药物组合物
KR20050110439A (ko) 퀴나졸린 유도체

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140910

Termination date: 20181101